



The Nutrition Society Irish Section Conference 2021 was held virtually on 22–24 June 2021

Conference on Nutrition, health and ageing – translating science into practice Symposium two: Anthropometric, lifestyle and dietary concerns in ageing – diagnostic and interventional considerations

Parkinson's disease: the nutrition perspective

Mícheál Ó Breasail^{1*}, Matthew D. Smith¹, Emma Tenison¹, Emily J. Henderson^{1,2} and Fiona E. Lithander¹

¹Population Health Sciences, Bristol Medical School, University of Bristol, 1-5 Whiteladies Road, Bristol BS8 1NU, UK

²Royal United Hospital Bath NHS Foundation Trust, Combe Park, Bath BA1 3NG, UK

Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease and affects about 1% of the population over the age of 60 years in industrialised countries. The aim of this review is to examine nutrition in PD across three domains: dietary intake and the development of PD; whole body metabolism in PD and the effects of PD symptoms and treatment on nutritional status. In most cases, PD is believed to be caused by a combination of genetic and environmental factors and although there has been much research in the area, evidence suggests that poor dietary intake is not a risk factor for the development of PD. The evidence about body weight changes in both the prodromal and symptomatic phases of PD is inconclusive and is confounded by many factors. Malnutrition in PD has been documented as has sarcopaenia, although the prevalence of the latter remains uncertain due to a lack of consensus in the definition of sarcopaenia. PD symptoms, including those which are gastrointestinal and non-gastrointestinal, are known to adversely affect nutritional status. Similarly, PD treatments can cause nausea, vomiting and constipation, all of which can adversely affect nutritional status. Given that the prevalence of PD will increase as the population ages, it is important to understand the interplay between PD, comorbidities and nutritional status. Further research may contribute to the development of interventional strategies to improve symptoms, augment care and importantly, enhance the quality of life for patients living with this complex neurodegenerative disease.

Parkinson disease: Parkinsonian disorders: Nutritional status

Parkinson's disease (PD) is the second most common neurodegenerative condition with an estimated prevalence of 1% in those over 60 years^(1,2). First described in 1817 in 'An Essay on the Shaking Palsy', James Parkinson described both the motor and non-motor features of the condition. Parkinsonism is a symptom complex consisting of akinesia, rigidity, tremor and postural instability, the latter of which tends to emerge as the

disease progresses. The onset of motor signs is often pre-dated by non-motor symptoms which encompass neuropsychiatric, sleep and autonomic dysfunction⁽³⁾. Nutrition is an often overlooked but important factor in the management of the disease; dysfunction is invariably multifactorial in aetiology, different features emerge over the disease course and vary in the degree to which they impact quality of life (Fig. 1).

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; DBS, deep brain stimulation; EWGSOP, European Working Group on Sarcopenia in Older Persons; MeDi, Mediterranean diet; PD, Parkinson's disease.

*Corresponding author: Mícheál Ó Breasail, email micheal.obreasail@bristol.ac.uk

†The online version of this article has been updated since original publication. A notice detailing the changes has also been published at <https://doi.org/10.1017/S0029665122000787>.




Fig. 1. Nutrition-related issues faced by patients with Parkinson's disease.

Idiopathic PD is the commonest cause of parkinsonism and is diagnosed clinically, usually with at least two of the four clinical signs in accordance with the UK Queens Square Brain Bank criteria⁽⁴⁾. Imaging has a supportive role particularly where features such as early falls, lack of response to levodopa, lack of tremor, rapid progression or dysautonomia raise the possibility of an alternative diagnosis⁽⁵⁾. The mainstay of treatment is focused on compensating for the primary loss of dopamine that results from presynaptic degeneration of dopaminergic cells in the substantia nigra and striatum. Dopaminergic drugs offer a gratifying response, particularly early in the disease. The heterogeneity of the disease is such that the choice of treatment regimen is highly individualised.

Hoehn and Yahr described five levels of clinical disability in PD from stage 1, in which there is unilateral involvement and minimal or no functional impairment, through to stage 5, in which the individual is confined to bed/wheelchair⁽⁶⁾. Although these stages may not correlate with pathophysiological stages, this scale aims to have practical utility and be reproducible when scored by different clinicians. The Movement Disorder Society-Unified Parkinson's Disease Rating Scale, which evaluates motor signs, the impact of motor and non-motor symptoms on daily living and motor complications, is the most widely used clinical rating scale for PD⁽⁷⁾. Macmahon and Thomas proposed a scale to describe the clinical course of PD from the 'diagnostic' phase; through a relatively stable 'maintenance' phase;



progressing to a 'complex' phase, characterised by motor fluctuations, development of cognitive impairment and appearance of axial symptoms, including falls, freezing of gait and dysphagia; finally reaching a palliative phase⁽⁸⁾. It is now recognised that several symptoms, in particular rapid-eye-movement sleep behaviour disorder, constipation, anosmia and depression, known as pre-motor symptoms, may precede the onset of motor symptoms by many years, during what is referred to as the 'prodromal' phase^(9,10).

Pathophysiology and aetiology of Parkinson's disease

PD is characterised pathologically by the loss of dopaminergic neurons in the substantia nigra, thought to be due to the accumulation within neurons of aggregated forms of the protein α -synuclein, known as Lewy bodies. By studying post-mortem brains from individuals with and without prior symptoms of parkinsonism, Braak and colleagues described a sequential progression of neuronal damage throughout the nervous system, categorised into six neuropathological stages: stage 1 consisting of lesions in the dorsal motor nucleus of the glossopharyngeal and vagal nerves, which later progress to reach the brainstem, finally involving the cerebral cortex in stage 6⁽¹¹⁾. Crucially, the hallmark lesions of PD were noted to develop before the clinical appearance of motor and non-motor dysfunction⁽¹¹⁾. In a subsequent neuropathological study, Braak and colleagues identified Lewy bodies within the myenteric and submucosal plexuses, the collections of neurons which comprise the enteric nervous system which controls the function of the gastrointestinal (GI) tract⁽¹²⁾. This has led to the suggestion that a neurotropic pathogen, which triggers PD pathology, may enter the central nervous system via a nasal and gastric route; the so-called 'dual-hit hypothesis'⁽¹³⁾.

A minority of patients with PD have a Mendelian form of the disease, such that the disease is caused by the inheritance of a single causative gene (e.g. SNCA, LRRK2, PARK2 and PINK1) in either an autosomal dominant or recessive pattern⁽¹⁴⁾. However, such cases of familial parkinsonism are rare and, in most cases, PD is believed to be caused by a combination of genetic and environmental factors. Genome-wide association studies look for variability across the genome to determine whether any identified SNPs occur at a differing frequency between PD cases and controls⁽¹⁵⁾. Multiple loci have been potentially implicated in PD⁽¹⁴⁾; these low penetrance variants, which each have only a minimal impact on risk, may collectively increase an individual's risk⁽¹⁵⁾. Similarly, numerous observational studies have examined the impact of environmental factors on the risk of PD, including dietary factors such as alcohol consumption and caffeine intake; exposure to environmental toxins, such as pesticides; biomarkers, such as BMI; drugs; comorbid illness and lifestyle factors including smoking⁽¹⁶⁾. However, apparent associations may not reflect a causal relationship due to potential residual confounding and reverse causation. There may also be

interactions between genetic and environmental risk factors such that the impact of any environmental factors is modified by the background genetic risk⁽¹⁷⁾.

In this review, we will examine nutrition in PD across three domains: dietary intake and the development of PD; whole body metabolism in PD including an overview of energy balance and musculoskeletal health and the effects of PD symptoms and treatment on nutritional status.

Dietary intake and the development of Parkinson's disease

Single nutrients

Oxidative stress plays a role in the development of PD^(18–20). Antioxidant vitamins such as vitamins A, C, E and β -carotene have established roles in reducing cell damage from free radicals, and there has been much interest in whether higher intake of these nutrients reduces PD risk. Data from the Health Professionals Follow-Up Study and the Nurses' Health Study cohorts suggest lower PD risk for the highest *v.* the lowest quintile of dietary vitamin E⁽²¹⁾, although at later follow-up, no association was found with vitamins C, E or carotenoids⁽²²⁾. In two Swedish cohorts, higher dietary β -carotene intake was associated with lower PD risk, and there was also an inverse association with vitamin C and E intake but only in women⁽²³⁾. Two meta-analyses suggest a neuroprotective effect of dietary vitamin E but not vitamins C and A or β -carotene^(24,25), although these predate more recent findings from the Health Professionals Follow-Up Study, the Nurses' Health Study and the Swedish cohort studies. Elevated plasma homocysteine has been described in neurodegenerative disorders^(26,27) and evidence suggests that polymorphisms in C₁ metabolism may increase PD risk⁽²⁸⁾. Due to the importance of B vitamins in C₁ metabolism⁽²⁶⁾, B₆, folate and B₁₂ have been investigated prospectively in the context of PD risk^(29,30) although the findings of these studies have been inconclusive.

The potential association between vitamin D intake and status has been explored with respect to PD risk^(31,32) and progression^(33,34) outwith of its established roles in musculoskeletal health⁽³⁵⁾. The literature in relation to vitamin D and the risk of developing PD has been distorted by several studies^(36–40), which, prior to retraction, influenced widely cited reviews and meta-analyses⁽⁴¹⁾. A Finnish cohort study reported an inverse relationship between serum 25-hydroxyvitamin D (25(OH)D) and PD risk in those in the highest and lowest quartiles⁽³¹⁾. In contrast, a Mendelian randomisation study reported a lack of support for a causal association between low 25(OH)D and risk of PD⁽³²⁾. Although there is limited evidence that vitamin D is protective against the development of PD⁽⁴²⁾, low serum 25(OH)D in those with established PD may partially explain poorer musculoskeletal health⁽⁴³⁾.

Macronutrients such as dietary fat and its individual fatty acids may influence PD risk, although there is significant heterogeneity in the literature^(44–49). Three meta-analyses, each with a different focus, investigated

the relationship between dietary fat and the risk of developing PD^(50–52). The first, by Kamel and colleagues, reported a negative association between total fat intake and PD risk⁽⁵⁰⁾. Although they demonstrated the same for dietary MUFA, SFA, PUFA, α -linolenic acid and linoleic acid, associations were greatest for α -linolenic acid and weakest for SFA⁽⁵⁰⁾. In contrast, Wang and colleagues found no association between total fat intake and PD risk, however, they did report an inverse relationship between PD risk and intake of total PUFA, *n*-3 PUFA, *n*-6 PUFA and linoleic acid⁽⁵¹⁾. The third study by Zhang and colleagues had a wider scope whereby they examined the relationship between fish and PUFA intake and PD risk in patients with mild-to-severe cognitive impairment⁽⁵²⁾. They reported that greater PUFA intake decreased PD risk, although not through the intake of the PUFAs DHA, EPA and α -linolenic acid⁽⁵²⁾. In summary, evidence about the intake of total fat and individual fatty acids is inconclusive and further research is needed in this area.

Food and food groups

Epidemiological evidence for the neuroprotective effects of caffeine-containing food and beverages, particularly from coffee and tea, emerged in the early 2000s^(53–61). Meta-analyses which included several of these cohorts in addition to smaller case-control studies^(62–69) have consistently found an inverse association between caffeine intake and PD risk^(70–72). Hong and colleagues also included PD cohorts and suggested that consuming caffeine may slow the rate of disease progression^(72–75). Recent case-control studies not included in these meta-analyses further support this inverse relationship between caffeine intake and PD risk⁽⁷⁶⁾. The novel treatment istradefylline, recently approved for the treatment in PD, acts at the same adenosine A_{2A} receptor as caffeine, which further supports this position⁽⁷⁷⁾.

Cohort studies report positive associations between dairy intake and the risk of developing PD^(46,58,78–81). In the Health Professionals Follow-Up Study and Nurses' Health Study cohorts, dairy intake was reported to be positively associated with PD; men consuming ≥ 2.9 servings/d had an 80% increased risk compared to those consuming < 1 serving/d⁽⁸⁰⁾. More recent data from these cohorts found total dairy intake was not significantly associated with PD, while low-fat dairy intake was⁽⁷⁸⁾, perhaps suggesting that the fat component of dairy foods may not increase PD risk⁽⁷⁸⁾. The American Cancer Society's Cancer Prevention Study II found a positive association between dairy consumption in both sexes and PD risk; those in the top quintile had a risk ratio 1.6 greater compared to the lowest⁽⁷⁹⁾. The Honolulu Heart Program which followed up men over 30 years, found those consuming the most milk (> 450 ml/d) had a 2.3-fold excess of PD *v.* non-milk drinkers, and no association was found for calcium from dairy or non-dairy sources⁽⁸¹⁾. In prospective cohorts in Greece and Finland, associations were also observed between milk consumption and the increased risk of PD^(46,58). In the Finnish cohort, a positive association was reported between reduced-fat dairy products and PD risk⁽⁵⁸⁾. A

meta-analysis including several of these studies^(46,58,79–81), estimated the absolute risk differences were two–four PD cases per 100 000 person-years for every 200 g/d increment in milk intake, and one–three PD cases per 100 000 person-years for every 10 g/d increment in cheese intake⁽⁸²⁾. In turn, this was included in two umbrella reviews which considered it as Class III evidence⁽¹⁶⁾ and low by AMSTAR and GRADE scores⁽⁸³⁾. Despite the positive associations between dairy intake and PD risk, there is currently not sufficient evidence to advise against dairy consumption at a population level.

Dietary patterns

Studies which focus on single nutrients and foods risk missing the synergistic effects at a whole diet level. Dietary patterns with well-established relationships to cardiovascular and metabolic health^(84–86) have been investigated for their potential neuroprotective properties^(58,87–89). Although many studies used the healthy eating index and alternate healthy eating index to explore relationships between diet and neurological outcomes, in recent years indices based on the 'Mediterranean diet' (MeDi) have generated greatest research interest⁽⁹⁰⁾. Data from two US cohorts found that those in the highest alternate healthy eating index and alternate Mediterranean diet score quintiles were 30 and 25%, respectively, less likely to develop PD *v.* the lowest⁽⁸⁸⁾; similar relationships were observed at later follow-up⁽⁹¹⁾. However, a Finnish cohort using a modified alternate healthy eating index found no such relationship⁽⁵⁸⁾. In a Greek population, MeDi adherence was associated with better cognitive performance and lower dementia rates⁽⁸⁹⁾, and subsequently it was reported that adherence was associated with fewer prodromal PD symptoms⁽⁹²⁾. In a cohort of over 47 000 Swedish women, greater adherence to a MeDi at middle age was associated with a lower risk for PD⁽⁹³⁾. Studies have examined a combined Mediterranean-Dietary Approaches to Stop Hypertension Diet Intervention for Neurodegenerative Delay^(94,95); Agarwal and colleagues found that it appeared to reduce PD risk and slow disease progression whereas neither the MeDi nor Dietary Approaches to Stop Hypertension diets alone achieved this⁽⁹⁵⁾. Moreover, in a smaller study, Metcalfe-Roach and colleagues found similar findings but in women only, whereas a Greek MeDi was protective in both sexes. There has been speculation that other diets such as the ketogenic, vegetarian and vegan can reduce PD risk although the evidence is limited⁽⁹⁶⁾. Interest in plant-based diets and PD stems from the protective attributes of the MeDi or other diets rich in fruit and vegetables⁽⁹⁷⁾, and the apparent lower prevalence of PD outside of North America and Europe, where animal-derived foods form a smaller proportion of dietary intake.

Whole body metabolism in Parkinson's disease

Impaired nutritional status is a common occurrence in patients once they have established features of PD and

weight loss may occur with PD progression, holding implications for treatment, quality of life and mortality. Numerous factors occur that may contribute to this process across the course of the condition, visually conceptualised in Fig. 2.

Body weight

One way in which nutritional dysfunction can be observed in PD is the variation in body weight that is observed throughout the lifespan of the disease. Conflicting results have been reported in epidemiological studies likely due to the considerable heterogeneity between different populations and varying stages of the condition when studied. The investigation of weight in populations with PD poses a multitude of difficulties with confounding occurring at a population level with various levels of obesity in the country in which the study was undertaken, coupled with confounders from comorbidities such as diabetes, as well as the drug treatment diet regimens. Furthermore, the possible existence of specific disease phenotypes in which weight loss may feature differentially may further complicate the picture⁽⁹⁸⁾. Weight loss in PD may predispose patients not only to an increased risk of malnutrition, but has been postulated to lead to the worsening of symptoms⁽⁹⁸⁾.

Changes in body weight may occur as a prodromal feature, before the typical symptoms of PD can be observed in an individual, however there are conflicting results. In a prospective study, Chen and colleagues demonstrated significant weight loss prior to diagnosis in over four hundred patients with PD⁽⁹⁹⁾. They suggested that the average weight of patients with PD was stable until shortly before diagnosis and then declined. However, in a case-control study, Ragonese and colleagues reported that no change in BMI occurred during the period preceding disease onset⁽¹⁰⁰⁾. Both studies used different methods and assessed two geographically disparate populations some decades apart. When symptomatic individuals with PD have been studied, the literature is also inconclusive. A low BMI in symptomatic individuals with PD, relative to healthy controls, has been demonstrated in a meta-analysis of twelve studies and in over eight hundred patients⁽¹⁰¹⁾. Weight variation over the disease course is of increasing interest and is relevant clinically as the therapeutic window of the drug treatments diminishes over time and therefore dosing needs to be reviewed in light of weight changes. Yong and colleagues found progressive weight loss in PD in a 3-year longitudinal study⁽¹⁰²⁾, whereas a further cross-sectional study of $n = 125$ adults with a median PD duration of 6 years reported unintentional weight loss in 38 and 50% of men and women, respectively⁽¹⁰³⁾. A study of a smaller cohort also suggested that BMI is low early in PD; however, a retrospective chart review was used to collect height and weight data in that instance⁽¹⁰⁴⁾. Other studies have shown no evidence of low weight or BMI in PD. Barichella and colleagues assessed BMI in $n = 364$ Italian men and women with a mean duration of PD of 10.6 years and found 65% of the cohort were overweight⁽¹⁰⁵⁾. Similarly, when compared with controls

in a cross-sectional study, overweight and obesity were more common among $n = 177$ Mexican patients with PD⁽¹⁰⁶⁾. Where it has been demonstrated, a low BMI in PD has been shown to increase the risk of cognitive decline⁽¹⁰⁷⁾, and is a risk factor for mortality, particularly in males⁽¹⁰⁸⁾, and has also been correlated with decreased olfaction⁽⁹⁸⁾. Early weight loss, occurring within the first year, has been associated with excess mortality⁽¹⁰⁹⁾.

Energy expenditure

Changes in energy expenditure have been investigated in PD. Increased energy expenditure has been demonstrated in a number of studies⁽¹¹⁰⁾ associated, in particular, with rigidity and the medication 'off' state which are periods of time in which symptoms significantly worsen, usually due to wearing off of dopaminergic medication^(111,112). Further studies have shown either no evidence of increased resting energy expenditure or even a lower energy expenditure associated with the decreased level of physical activity that occurs due to disability in PD^(113,114). Investigating this association is likely confounded by the dynamic nature of 'off' and 'on' medication states and the influence of varying medication states that can change throughout the course of a day.

The symptom of tremor, which predominantly occurs at rest, is a potential cause of an increase in energy expenditure. This association has seldom been investigated aside from extrapolation based on the observation of weight gain following deep brain stimulation (DBS) surgery⁽¹¹⁵⁾. In contrast, in studies where DBS has been carried out for the unlinked condition of essential tremor, weight gain has not been shown to be significant, disputing the link to increased energy expenditure due to excess movement from tremor⁽¹¹⁶⁾. Excess energy can also be spent with the excessive movement associated with dyskinesia, a fidgeting-like motion occurring due to a paradoxical surfeit of dopamine. This is common in association with levodopa therapy, with the risk worsening throughout the disease course, and is associated with a decreased body weight⁽¹⁰²⁾. The link of DBS with weight gain may also be a function of this negative effect of dyskinesia on weight, as one of the primary indications for undertaking DBS is to improve the nature of dyskinesia, particularly by reducing required levodopa dosing. Additionally, a central metabolic effect may be observed given the close proximity of one DBS target, the subthalamic nucleus, to the hypothalamus⁽¹¹⁷⁾.

Energy intake

Alterations in energy intake have also been found in PD. Changes in the quality of the diet may be driven by specific cognitive changes pertaining to food selection or as part of an impulse control disorder, the latter of which may be related to dopaminergic medication⁽¹¹⁸⁾. Compulsive eating has been documented in PD, with one case-control study suggesting that 25% of patients with PD consumed excessive energy compared with 12% of healthy controls⁽¹¹⁹⁾. This can manifest as binge-eating and correlates with the presence of anxiety more strongly than medication type or dose⁽¹²⁰⁾.




Fig. 2. Putative representation of the dynamic and interacting factors that impact nutritional status in Parkinson's disease. GI, gastrointestinal; M & T, MacMahon and Thomas⁽⁶⁾; H & Y, Hoehn and Yahr⁽⁶⁾.

Dietary intake in PD may be subtly affected by more than simply over-eating, with several studies suggesting a preference for sweet foods including chocolate, cakes and ice cream, even relative to household controls^(121–124). Higher carbohydrate intake, associated with lower protein, folate, magnesium and phosphorus intake has also been observed⁽¹²⁵⁾. Other studies have examined the intake of food groups and low intake of fruit, vegetables and meat has been observed⁽¹²¹⁾. The dopaminergic system is highly implicated in reward and motivation, and dysfunction likely contributes to the pattern of abnormal eating observed in PD, as suggested empirically by the association of dopamine agonist therapy with overeating. It has been suggested that overeating of rewarding foods that triggers a small dopamine 'hit' may be in response to the more generalised hypodopaminergic state that defines PD⁽¹²⁵⁾.

Metabolic homeostasis

Evidence for dysfunction of metabolic homeostasis has been found in PD, in particular pathology affecting the hypothalamus as demonstrated in post-mortem and functional imaging studies⁽¹¹⁰⁾. Decreased orexin is observed in the cerebrospinal fluid of individuals with PD^(126,127), although correlation with weight has not been undertaken. Decreased ghrelin is observed in the plasma of patients with PD who experience weight loss. This suggests a degree of neurohormonal dysregulation, with an opposite relationship (an increase) usually observed with weight loss in healthy subjects^(127,128). Decreased dynamic control of ghrelin has been demonstrated at prodromal stages, prompting the question of whether this is an early symptomatic change or causative

mechanism⁽¹²⁹⁾. Although conflicting results for leptin levels have been published in recent years, a recent meta-analysis suggested that this remains normal⁽¹³⁰⁾. Evidence exists for a role of mitochondrial dysfunction in the aetiology of PD⁽¹³¹⁾, suggesting that an intrinsic dysfunction of energy handling may exist in affected individuals, with neuronal cells particularly sensitive to abnormalities of cellular respiration.

Malnutrition, muscle and bone

Malnutrition is common in older adults and is prevalent in PD. In a systematic review, Sheard and colleagues assessed the prevalence in over 1100 patients with PD in eleven studies. The mean age of the PD samples ranged from 54 to 75 years and the duration of the disease ranged from 5 to 13 years. Irrespective of whether the patient was hospitalised, measured in a PD clinic or living in the community, the prevalence of malnutrition in PD ranged from 0 to 24% and the risk of malnutrition from 3 to 60%⁽¹³²⁾. Other studies of either hospitalised patients⁽¹³³⁾ or those attending an outpatient clinic⁽¹³⁴⁾ support this finding, although different methods were used to measure malnutrition across the studies. In addition to being at an increased risk of malnutrition because of the symptoms of PD, the treatment used to manage PD may also increase malnutrition risk⁽¹³²⁾.

Malnutrition is a known risk factor for sarcopaenia^(135–137), the age-related loss of muscle and strength^(138,139), which combined with low serum 25(OH)D in PD may negatively impact muscle strength and balance, increasing falls risk⁽³⁵⁾. Determining the prevalence of sarcopaenia in PD is complicated by a lack of consensus and a multitude of clinical definitions in widespread use. These include The

European Working Group on Sarcopenia in Older Persons (EWGSOP-1 and EWGSOP-2)^(139,140), Foundation of the National Institutes of Health⁽¹⁴¹⁾ and International Working Group on Sarcopenia⁽¹⁴²⁾ definitions. Although the European Society for Parenteral and Enteral Nutrition guideline for clinical nutrition in neurology suggests that sarcopaenia risk in PD is low⁽¹⁴³⁾ they cite only a single study that used a clinical definition of sarcopaenia. This study of Italians with parkinsonian syndromes ($n = 364$) reported a prevalence of 7% using the EWGSOP-1 definition⁽¹⁴⁴⁾. Several more recent studies have reported higher rates. A Turkish case-control study ($n = 155$) used EWGSOP-1 and reported a prevalence of 50% in PD and 31% in controls⁽¹⁴⁵⁾, whereas a Brazilian study reported a prevalence of 22% in PD using EWGSOP-2 compared to 55% with EWGSOP-1⁽¹⁴⁶⁾. A recent Malaysian study reported a prevalence of 26% in PD using EWGSOP-2 and 4% in controls⁽¹⁴⁷⁾, greater than previous Malaysian rates based on The Asian Working Group on Sarcopenia criteria⁽¹⁴⁸⁾. Vetrano and colleagues compared the criteria and found the prevalence of sarcopaenia in PD varied between 29 and 41% in men and 18 and 33% in women, with poor agreement between EWGSOP-1, Foundation of the National Institutes of Health and IGWS⁽¹⁴⁹⁾.

Although in a young healthy individual, a fall from standing height would not likely result in a fracture, in PD, reduced bone mineral density^(150–152) and a higher frequency of falls increase fracture risk^(43,153–159). Studies suggest that in PD, osteoporosis and fracture are twice as likely^(150,160,161), and in women, PD is the strongest single contributor to fracture risk⁽¹⁶²⁾. Patients with PD also appear to have a greater prevalence of hip fracture^(163–165), which is associated with increased morbidity and mortality^(166,167). Of particular relevance to bone health, a number of case-control studies have suggested serum 25(OH)D is reduced in PD^(33,34,43,168–170), and those with lower 25(OH)D have a greater frequency of falls⁽⁴³⁾. Given the vital role that nutrition plays in musculoskeletal function, further research would be valuable to specifically determine the benefit of dietary interventions on bone health and fracture risk.

The effects of Parkinson's disease symptoms and treatment on nutritional status

Gastrointestinal symptoms

Anosmia and dysgeusia. Anosmia is a frequently reported symptom in PD, often occurring many years before the onset of motor symptoms and affecting up to 90% of patients⁽¹⁷¹⁾. Ageusia is less commonly reported, however taste is heavily dependent on the sense of smell and the two interlinked may affect up to 27% of patients with PD⁽¹⁷²⁾. Other symptoms such as xerostomia may contribute to taste abnormalities. A decreased sense of smell and taste is known to negatively influence nutritional status⁽¹⁷³⁾. On examination of the relationship between anosmia, dysgeusia and body weight, it was found that olfactory and gustatory deficits may negatively influence weight⁽¹⁷⁴⁾. In a prospective study of patients

with PD, Sharma and Turton found that 39% of patients were characterised as 'weight losers' and 60% as 'non-weight losers', with 'weight losers' more likely to be older, female and have more severe olfactory impairment⁽⁹⁸⁾. Since smell is an important aspect of food appeal, it is possible that altered olfaction can negatively impact dietary intake that may be important in the pathophysiology of PD⁽¹²⁵⁾. Ådén and colleagues found associations between a lower intake of nutrients such as protein and olfactory function in patients newly diagnosed with PD compared to a control group⁽¹²⁵⁾. Roos and colleagues suggested that hyposmia, and not hypogeusia, may contribute to weight loss in PD and hence increase the risk of malnutrition. This cross-sectional study found a significant correlation between olfactory function and BMI, but not between gustatory function and BMI⁽¹⁷⁵⁾.

Dysphagia and the oral cavity. Dysphagia is common in PD, having an estimated symptomatic prevalence of 35% based on a meta-analysis of ten studies. The prevalence is further increased to 82% when considering objective measures of swallowing function⁽¹⁷⁶⁾, suggesting that asymptomatic dysphagia is widespread and occurs silently. Symptoms arise due to the disruption of swallowing at all stages of the process including the oral stage (reduced oral bolus control), pharyngeal phase (impaired coordination of pharyngeal structures) and the oesophageal stage (impaired sphincter relaxation)⁽¹⁷⁷⁾. Hypersalivation or conversely xerostomia that can be linked to levodopa therapy are other factors that may impair the swallowing of food⁽¹⁷⁸⁾. Patients with PD also suffer from worse dentition than similarly aged individuals, further impairing their ability to eat, with tooth decay in turn contributed to by xerostomia⁽¹⁷⁹⁾. Orofacial pain phenomena such as burning mouth syndrome occur at an increased prevalence in PD, causing potential distress with eating⁽¹⁸⁰⁾. Facial and lip tremors may also occur, affecting confidence with eating⁽¹⁸¹⁾. Each of these factors can individually or collectively impair dietary intake and have a negative impact on nutritional status. Moreover, difficulties ingesting food may impair the intake of specific micronutrients such as vitamin D and calcium, subsequently increasing the risk of osteoporosis and fracture risk. Swallowing issues can also affect quality of life⁽¹⁸²⁾ which may be directly through embarrassment in social situations, or due to fear induced by choking episodes, as well as the impact that dysphagia can have on dietary intake. The presence of dysphagia is a risk factor for adverse outcomes such as pneumonia through silent aspiration, a primary cause of death associated with PD⁽¹⁸³⁾.

Changes to the gut microbiome. Small bowel gastrointestinal overgrowth has been commonly observed in PD, affecting an estimated 46% of patients and is characterised by an overgrowth of bacterial colonies beyond normally observed limits or the growth of abnormal types⁽¹⁸⁴⁾. Diagnosis relies on the use of a hydrogen breath test to infer overgrowth, as used in studies defining prevalence in PD, although the gold standard is the physical culture of jejunal aspirate. The

gut microbiome in PD is well documented to be abnormal relative to healthy controls and the overabundance of particular species are associated with the risk of GI symptoms in PD such as constipation⁽¹⁸⁵⁾. Vitamin B₁₂ deficiency can result from the consumption of this vitamin by anaerobic micro-organisms⁽¹⁸⁶⁾ and bacteria can disrupt bile acid which adversely affects the absorption of fat and fat-soluble vitamins⁽¹⁸⁶⁾. Hasuike and colleagues hypothesised that bacterial overgrowth has various effects via bile acid metabolism in PD⁽¹⁸⁷⁾. It has been suggested that serum bilirubin increases as bilirubin metabolism declines with decreases in the intestinal bacteria⁽¹⁸⁷⁾. Simultaneously, bile acid is degraded due to increased intestinal bacteria, and lipid absorption decreases leading to low serum TAG levels and loss of body mass⁽¹⁸⁷⁾. Similarly, there is decreased absorption of vitamin D aligned with a decrease in bile acid, a risk factor for osteoporosis and fractures. It is clear that consideration needs to be given to the hypothesis that some of the non-motor manifestations accompanying PD are caused by intestinal dysbiosis⁽¹⁸⁷⁾. *Helicobacter pylori* (*H. pylori*) infection has been linked to PD, with higher rates of infection observed PD⁽¹⁸⁸⁾. The benefit of eradication therapy has been addressed and is linked to improved outcomes such as UPDRS score and 'on' time⁽¹⁸⁹⁾, suggesting that untreated infection may impair levodopa absorption.

Constipation. The most commonly recognised GI symptom in PD is constipation, referring to both difficulty defecating and a decreased frequency of stool, and affects between 20 and 81% of patients⁽¹⁹⁰⁾. Constipation can be observed as a prodromal symptom predating the onset of defining motor symptoms⁽¹⁹¹⁾, and is linked to worse outcomes that include earlier onset of dementia⁽¹⁹²⁾. Symptoms arise from the degeneration of brain structures involved in controlling defecatory storage and expulsion, as well as the nerves of the myenteric plexus within the bowel that control motility⁽¹⁹³⁾. A similar effect on motility can also be observed in the upper GI tract, causing delayed gastric emptying⁽¹⁹⁴⁾ and both can adversely affect quality of life. Bowel motility issues also affect dopaminergic medication absorption⁽¹⁹⁵⁾, worsening motor control and cause further impact on quality of life. Constipation is a risk factor for malnutrition⁽¹⁹⁶⁾. In a sample of community-dwelling patients with PD, nutritional status was measured using two validated tools: the Subjective Global Assessment and the Patient-Generated Subjective Global Assessment⁽¹⁹⁷⁾. Forty three percent of the cohort reported previous unintentional weight loss following diagnosis, and 15% were moderately malnourished wherein constipation was one of the symptoms reported to adversely affect dietary intake⁽¹⁰³⁾. Sheard and colleagues assessed nutritional status using the Patient-Generated Subjective Global Assessment in patients with PD awaiting DBS surgery, and of the nutrition impact symptoms listed, 58% recorded that constipation adversely affected their dietary intake over the previous 2 weeks⁽¹⁹⁸⁾. In a cross-sectional study of PD in China, constipation was considered to be one of the two most important predictors of nutritional

impairment⁽¹⁹⁹⁾. Delayed gastric emptying and the resultant nausea, bloating and early satiety⁽¹⁹⁴⁾ can adversely affect appetite and in turn dietary intake, and increase the risk of malnutrition in this patient group.

The effect of non-gastrointestinal symptoms on nutritional status

Difficulty with eating. Patients with PD experience a motor disorder that affects manual dexterity and control, therefore leading to problems with the physical act of eating. Difficulty manipulating food on the plate and transporting it to the mouth accurately is observed with the risk of spillage due to tremor⁽²⁰⁰⁾. Increased upper limb tremor has been associated with a lower energy intake, as has the observation of fewer spoonfuls being taken during a meal by individuals with advanced stage disease⁽²⁰¹⁾ and represents the direct effect of the cardinal motor features of PD on the risk of malnutrition.

Cognition. In PD, cognitive impairment is a common symptom later in the disease course. Specific decline in frontal lobe function has been shown to correlate with the BMI, fitting with the potential sweet food preference that can be observed in frontal executive dysfunction⁽²⁰²⁾. Cognitive impairment as it progresses becomes a risk factor for becoming dependent on others for food intake⁽²⁰³⁾. Individuals are less likely to ask for food and less likely to be able to physically prepare or access food at will due to motor disability in PD, especially in an environment that is unfamiliar such as physical care settings. Overall, the prevalence of malnutrition in care homes is high, estimated at approximately 15% worldwide⁽²⁰⁴⁾. This may be impacted by staffing constraints commonly encountered in such environments, and a lack of social interaction may also remove some aspects of reward associated with eating⁽²⁰⁵⁾. Depression is also a common occurrence in PD and may also negatively influence volition to eat with a demonstrated association of weight loss^(206,207).

The effect of treatment on nutritional status

Dopaminergic-based treatments for PD primarily target motor symptoms, but are associated with recognised side-effects (Table 1). Dopaminergic medication, including levodopa, dopamine agonists and catechol-*O*-methyltransferase inhibitors commonly cause nausea and vomiting which is usually transient during an initial period of acclimatisation, but may adversely affect dietary intake in the short term. Dopamine agonist medications are associated with weight gain in the long term^(208,209), potentially due to an increased incidence of compulsive eating associated with impulse control disorder. Levodopa use has conversely been associated with a decrease in body weight, although historically dopamine agonists have been used in earlier disease and may therefore simply be a function of disease staging. Weight loss is also observed with levodopa intestinal gel-infusions; however, this is also a treatment reserved for late-stage disease⁽²¹⁰⁾. Dyskinesia is another

Table 1. Common medications and their effects on nutritional status

Drug	Mode of action	Side effects
Levodopa	A large neutral amino acid absorbed in the small intestine. Once absorbed, it crosses the blood–brain barrier where it is converted to dopamine, supplementing endogenous levels	Nausea, vomiting, hypotension. Associated with hyper-homocysteinaemia
Dopamine agonists	A further approach to improving dopaminergic signalling in the brain, directly activating dopamine receptors. Used less frequently due to the risk of impulse control disorder side-effects	Nausea and vomiting
MAO-B inhibitors	Used in the early stages of Parkinson's to delay the use of levodopa. Provides reduced motor fluctuations and increased 'on' time. Most commonly used as 'add-on' therapy but can be effective as a primary treatment	Can cause insomnia
Anti-cholinergics	Used for the treatment of tremor or bladder symptoms. Use is limited in practice due to potential effect on cognitive function	Xerostomia, constipation and nausea
Amantadine	Antiviral agent that may increase dopamine release by blocking dopamine re-uptake and NMDA receptor antagonism	Confusion, hallucinations, insomnia, nightmares and dry mouth

MAO, monoamine oxidase type B; NMDA, *N*-methyl-D-aspartate.

Adapted from BDA Best Practice guidance for dietitians on the nutritional management of Parkinson's, 2021⁽²¹⁹⁾.

common phenomena related to levodopa therapy and is associated with increased weight loss⁽¹⁰²⁾.

Medications can also influence the handling of nutrients important for metabolism. As such, raised homocysteine levels are observed in those patients with oral levodopa dosing and decreased vitamins B₁₂, B₆ and folate levels associated with intestinal gel use^(211,212). As described previously, DBS has been found to be consistently associated with weight gain. This may result from an improvement in dyskinesia, a primary indication for this therapy, thus reducing overall energy expenditure⁽²¹³⁾.

Nutritional status is known to affect the response to PD treatments, likely by affecting pharmacokinetic handling. Individuals with lower body weight are at an increased risk of peak-dose dyskinesia on levodopa, with a greater area under the curve exposure and longer elimination observed, necessitating the consideration of weight and anticipation of ongoing nutritional care when dosing^(214–216). When normalised for body weight and adjusted for age, sex and disease severity, levodopa has been associated with the impaired nutritional status in a dose-dependent manner⁽²¹⁷⁾. In addition, a cumulative dose of levodopa has been reported to be associated with micronutrient deficiency through changes in homocysteine, vitamin B₆ and B₁₂ levels⁽²¹⁸⁾. Other common medications used in the treatment of PD and the effects that they may have on nutritional status are described in Table 1⁽²¹⁹⁾.

Conclusions and future research

We have presented an overview of nutrition in PD in this review and have covered three domains: dietary intake and the development of PD; whole body metabolism in PD, including energy balance and musculoskeletal health and the effects of PD symptoms and treatment on nutritional status. We have highlighted areas where future research on the effect of PD on nutritional status is particularly relevant and important. Determining modifiable risk

factors for PD with further research specifically on Mediterranean-style diets in particular, the Mediterranean-Dietary Approaches to Stop Hypertension Diet Intervention for Neurodegenerative Delay diet, could be vital in enhancing our knowledge of the pathophysiology of PD and therefore the development of novel treatments for the condition. Additionally, there is evidence that patients with PD are at risk of malnutrition and a better understanding of the mechanisms behind this is important in developing holistic care to optimise outcomes and quality of life.

Little is known about appetite in PD aside from limited studies that explore a tendency towards certain foods. Additionally, the burden of disability that can affect dexterity, cognitive impairment and the motor impairments that negatively impact the physical act of eating have not yet been fully determined. Tackling this need would enable techniques to be developed to assist with eating and thus improve nutritional status in this patient group. We have highlighted the studies that have sought to characterise patients' weight in the years before the onset of symptoms. Further research will allow us to understand the role of weight change in the pathophysiology of PD, addressing the question of whether weight change is integral to the underlying pathology or merely an additional early symptom.

Much has been discussed about the link between PD and the GI tract, archetyped by the Braak hypothesis⁽¹¹⁾ although currently only circumstantial evidence exists. The role played by empirically observed phenomena such as small bowel gastrointestinal overgrowth is not yet fully understood, in particular the extent to which this is important in the prodromal phase, nor is the impact of *H. pylori* infection, where the impact on dyskinesia is not yet clear. Adequately powered and well-designed randomised controlled trials are required to assess these links.

A better understanding of the role that nutritional factors play in aetiology will further understand and may, in due course, contribute to developing interventional

strategies to augment care and improve symptoms for patients living with this complex and multifactorial neurodegenerative disease.

Acknowledgements

We gratefully acknowledge the input of Stephanie Drake who illustrated Fig. 1 on behalf of the authors.

Financial Support

All authors receive salary support from the Gatsby Foundation.

Conflict of Interest

None.

Authorship

The authors were solely responsible for all aspects of preparation of the present review.

References

- Parkinson J (2002) An essay on the shaking palsy. 1817. *J Neuropsychiatry Clin Neurosci* **14**, 223–236, discussion 222.
- de Lau LM & Breteler MM (2006) Epidemiology of Parkinson's disease. *Lancet Neurol* **5**, 525–535.
- Chaudhuri KR, Healy DG & Schapira AH (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. *Lancet Neurol* **5**, 235–245.
- Hughes AJ, Daniel SE, Kilford L *et al.* (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J Neurol Neurosurg Psychiatry* **55**, 181–184.
- Suchowersky O, Reich S, Perlmutter J *et al.* (2006) Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) [RETIRED]. Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* **66**, 968–975.
- Hoehn MM & Yahr MD (1967) Parkinsonism: onset, progression and mortality. *Neurology* **17**, 427–442.
- Goetz CG, Tilley BC, Shaftman SR *et al.* (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Mov Disord* **23**, 2129–2170.
- MacMahon DG & Thomas S (1998) Practical approach to quality of life in Parkinson's disease: the nurse's role. *J Neurol* **245**(Suppl 1), S19–S22.
- Schrag A, Horsfall L, Walters K *et al.* (2015) Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. *Lancet Neurol* **14**, 57–64.
- Kaiserova M, Grambalova Z, Kurcova S *et al.* (2021) Premotor Parkinson's disease: overview of clinical symptoms and current diagnostic methods. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* **165**, 103–112.
- Braak H, Del Tredici K, Rüb U *et al.* (2003) Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging* **24**, 197–211.
- Braak H, de Vos RA, Bohl J *et al.* (2006) Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. *Neurosci Lett* **396**, 67–72.
- Hawkes CH, Del Tredici K & Braak H (2007) Parkinson's disease: a dual-hit hypothesis. *Neuropathol Appl Neurobiol* **33**, 599–614.
- Lill CM, Roehr JT, McQueen MB *et al.* (2012) Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. *PLoS Genet* **8**, e1002548.
- Vázquez-Vélez GE & Zoghbi HY (2021) Parkinson's disease genetics and pathophysiology. *Annu Rev Neurosci* **44**, 87–108.
- Bellou V, Belbasis L, Tzoulaki I *et al.* (2016) Environmental risk factors and Parkinson's disease: an umbrella review of meta-analyses. *Parkinsonism Relat Disord* **23**, 1–9.
- Jacobs BM, Belete D, Bestwick J *et al.* (2020) Parkinson's disease determinants, prediction and gene–environment interactions in the UK Biobank. *J Neurol Neurosurg Psychiatry* **91**, 1046–1054.
- Trist BG, Hare DJ & Double KL (2019) Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease. *Aging Cell* **18**, e13031.
- Subramaniam SR & Chesselet MF (2013) Mitochondrial dysfunction and oxidative stress in Parkinson's disease. *Prog Neurobiol* **106–107**, 17–32.
- Puspita L, Chung SY & Shim JW (2017) Oxidative stress and cellular pathologies in Parkinson's disease. *Mol Brain* **10**, 53.
- Zhang SM, Hernán MA, Chen H *et al.* (2002) Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. *Neurology* **59**, 1161–1169.
- Hughes KC, Gao X, Kim IY *et al.* (2016) Intake of antioxidant vitamins and risk of Parkinson's disease. *Mov Disord* **31**, 1909–1914.
- Yang F, Wolk A, Håkansson N *et al.* (2017) Dietary antioxidants and risk of Parkinson's disease in two population-based cohorts. *Mov Disord* **32**, 1631–1636.
- Etminan M, Gill SS & Samii A (2005) Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. *Lancet Neurol* **4**, 362–365.
- Takeda A, Nyssen OP, Syed A *et al.* (2014) Vitamin A and carotenoids and the risk of Parkinson's disease: a systematic review and meta-analysis. *Neuroepidemiology* **42**, 25–38.
- Selhub J (2002) Folate, vitamin B₁₂ and vitamin B₆ and one carbon metabolism. *J Nutr Health Aging* **6**, 39–42.
- Coppède F (2021) One-carbon epigenetics and redox biology of neurodegeneration. *Free Radic Biol Med* **170**, 19–33.
- Murray LK & Jadavji NM (2019) The role of one-carbon metabolism and homocysteine in Parkinson's disease onset, pathology and mechanisms. *Nutr Res Rev* **32**, 218–230.
- de Lau LM, Koudstaal PJ, Witteman JC *et al.* (2006) Dietary folate, vitamin B₁₂, and vitamin B₆ and the risk of Parkinson disease. *Neurology* **67**, 315–318.
- Chen H, Zhang SM, Schwarzschild MA *et al.* (2004) Folate intake and risk of Parkinson's disease. *Am J Epidemiol* **160**, 368–375.

31. Knekt P, Kilkkinen A, Rissanen H *et al.* (2010) Serum vitamin D and the risk of Parkinson disease. *Arch Neurol* **67**, 808–811.
32. Larsson SC, Singleton AB, Nalls MA *et al.* (2017) No clear support for a role for vitamin D in Parkinson's disease: a Mendelian randomization study. *Mov Disord* **32**, 1249–1252.
33. Evatt ML, DeLong MR, Khazai N *et al.* (2008) Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. *Arch Neurol* **65**, 1348–1352.
34. Ding H, Dhima K, Lockhart KC *et al.* (2013) Unrecognized vitamin D₃ deficiency is common in Parkinson disease: Harvard biomarker study. *Neurology* **81**, 1531–1537.
35. Hiller AL, Murchison CF, Lobb BM *et al.* (2018) A randomized, controlled pilot study of the effects of vitamin D supplementation on balance in Parkinson's disease: does age matter? *PLoS One* **13**, e0203637–e0203637.
36. Sato Y, Honda Y & Iwamoto J (2007) Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. *Neurology* **68**, 911–915.
37. Sato Y, Honda Y & Iwamoto J (2016) Erratum: Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease (*Neurology* (2007) 68 (911–915) DOI: 10.1212/01.wnl.0000257089.50476.92). *Neurology* **87**, 239.
38. Sato Y, Honda Y, Iwamoto J *et al.* (2005) Abnormal bone and calcium metabolism in immobilized Parkinson's disease patients. *Mov Disord* **20**, 1598–1603.
39. Sato Y, Honda Y, Iwamoto J *et al.* (2019) Retracted: Abnormal bone and calcium metabolism in immobilized Parkinson's disease patients (*Movement Disorders*, (2005), 20, 12, (1598–1603), 10.1002/mds.20658). *Movement Disorders* **34**, 156.
40. Sato Y, Honda Y, Kaji M *et al.* (2002) RETRACTED: Amelioration of osteoporosis by menatetrenone in elderly female Parkinson's disease patients with vitamin D deficiency. *Bone* **31**, 114–118.
41. Hiller A (2021) Response to the retraction of papers by Yoshihiro Sato – a review of vitamin D and Parkinson's disease. *Maturitas* **148**, 54.
42. Fullard ME & Duda JE (2020) A review of the relationship between vitamin D and Parkinson disease symptoms. *Front Neurol* **11**, 454–454.
43. Zhang H-J, Zhang J-R, Mao C-J *et al.* (2019) Relationship between 25-hydroxyvitamin D, bone density, and Parkinson's disease symptoms. *Acta Neurol Scand* **140**, 274–280.
44. Chen H, Zhang SM, Hernán MA *et al.* (2003) Dietary intakes of fat and risk of Parkinson's disease. *Am J Epidemiol* **157**, 1007–1014.
45. Dong J, Beard JD, Umbach DM *et al.* (2014) Dietary fat intake and risk for Parkinson's disease. *Mov Disord* **29**, 1623–1630.
46. Kyroziis A, Ghika A, Stathopoulos P *et al.* (2013) Dietary and lifestyle variables in relation to incidence of Parkinson's disease in Greece. *Eur J Epidemiol* **28**, 67–77.
47. de Lau LM, Bornebroek M, Witteman JC *et al.* (2005) Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study. *Neurology* **64**, 2040–2045.
48. Abbott RD, Ross GW, White LR *et al.* (2003) Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia aging study. *J Neurol* **250**(Suppl 3), Iii30–Iii39.
49. Tan LC, Methawasini K, Tan EK *et al.* (2016) Dietary cholesterol, fats and risk of Parkinson's disease in the Singapore Chinese health study. *J Neurol Neurosurg Psychiatry* **87**, 86–92.
50. Kamel F, Goldman SM, Umbach DM *et al.* (2014) Dietary fat intake, pesticide use, and Parkinson's disease. *Parkinsonism Relat Disord* **20**, 82–87.
51. Wang A, Lin Y, Wu Y *et al.* (2015) Macronutrients intake and risk of Parkinson's disease: a meta-analysis. *Geriatr Gerontol Int* **15**, 606–616.
52. Zhang Y, Chen J, Qiu J *et al.* (2016) Intakes of fish and polyunsaturated fatty acids and mild-to-severe cognitive impairment risks: a dose-response meta-analysis of 21 cohort studies. *Am J Clin Nutr* **103**, 330–340.
53. Ross GW, Abbott RD, Petrovitch H *et al.* (2000) Association of coffee and caffeine intake with the risk of Parkinson disease. *JAMA* **283**, 2674–2679.
54. Kim IY, O'Reilly É J, Hughes KC *et al.* (2017) Differences in Parkinson's disease risk with caffeine intake and postmenopausal hormone use. *J Parkinsons Dis* **7**, 677–684.
55. Ascherio A, Zhang SM, Hernán MA *et al.* (2001) Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. *Ann Neurol* **50**, 56–63.
56. Ascherio A, Weisskopf MG, O'Reilly EJ *et al.* (2004) Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. *Am J Epidemiol* **160**, 977–984.
57. Ascherio A, Chen H, Schwarzschild MA *et al.* (2003) Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. *Neurology* **60**, 790–795.
58. Sääksjärvi K, Knekt P, Lundqvist A *et al.* (2013) A cohort study on diet and the risk of Parkinson's disease: the role of food groups and diet quality. *Br J Nutr* **109**, 329–337.
59. Palacios N, Gao X, McCullough ML *et al.* (2012) Caffeine and risk of Parkinson's disease in a large cohort of men and women. *Mov Disord* **27**, 1276–1282.
60. Tan LC, Koh WP, Yuan JM *et al.* (2008) Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese health study. *Am J Epidemiol* **167**, 553–560.
61. Hu G, Bidel S, Jousilahti P *et al.* (2007) Coffee and tea consumption and the risk of Parkinson's disease. *Mov Disord* **22**, 2242–2248.
62. Tan EK, Chua E, Fook-Chong SM *et al.* (2007) Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers. *Pharmacogenet Genomics* **17**, 1001–1005.
63. Paganini-Hill A (2001) Risk factors for Parkinson's disease: the leisure world cohort study. *Neuroepidemiology* **20**, 118–124.
64. Wirdefeldt K, Gatz M, Pawitan Y *et al.* (2005) Risk and protective factors for Parkinson's disease: a study in Swedish twins. *Ann Neurol* **57**, 27–33.
65. Fall PA, Fredrikson M, Axelson O *et al.* (1999) Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in south-eastern Sweden. *Mov Disord* **14**, 28–37.
66. Benedetti MD, Bower JH, Maraganore DM *et al.* (2000) Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. *Neurology* **55**, 1350–1358.
67. Checkoway H, Powers K, Smith-Weller T *et al.* (2002) Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. *Am J Epidemiol* **155**, 732–738.

68. Ragonese P, Salemi G, Morgante L *et al.* (2003) A case-control study on cigarette, alcohol, and coffee consumption preceding Parkinson's disease. *Neuroepidemiology* **22**, 297–304.
69. Tanaka K, Miyake Y, Fukushima W *et al.* (2011) Intake of Japanese and Chinese teas reduces risk of Parkinson's disease. *Parkinsonism Relat Disord* **17**, 446–450.
70. Liu R, Guo X, Park Y *et al.* (2012) Caffeine intake, smoking, and risk of Parkinson disease in men and women. *Am J Epidemiol* **175**, 1200–1207.
71. Qi H & Li S (2014) Dose–response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease. *Geriatr Gerontol Int* **14**, 430–439.
72. Hong CT, Chan L & Bai C-H (2020) The effect of caffeine on the risk and progression of Parkinson's disease: a meta-analysis. *Nutrients* **12**, 1860.
73. Moccia M, Erro R, Picillo M *et al.* (2016) Caffeine consumption and the 4-year progression of de novo Parkinson's disease. *Parkinsonism Relat Disord* **32**, 116–119.
74. Kandinov B, Giladi N & Korczyn AD (2009) Smoking and tea consumption delay onset of Parkinson's disease. *Parkinsonism Relat Disord* **15**, 41–46.
75. Scott NW, Macleod AD & Counsell CE (2016) Motor complications in an incident Parkinson's disease cohort. *Eur J Neurol* **23**, 304–312.
76. Bakshi R, Macklin EA, Hung AY *et al.* (2020) Associations of lower caffeine intake and plasma urate levels with idiopathic Parkinson's disease in the Harvard biomarkers study. *J Parkinsons Dis* **10**, 505–510.
77. Torti M, Vacca L & Stocchi F (2018) Istradefylline for the treatment of Parkinson's disease: is it a promising strategy? *Expert Opin Pharmacother* **19**, 1821–1828.
78. Hughes KC, Gao X, Kim IY *et al.* (2017) Intake of dairy foods and risk of Parkinson disease. *Neurology* **89**, 46–52.
79. Chen H, O'Reilly E, McCullough ML *et al.* (2007) Consumption of dairy products and risk of Parkinson's disease. *Am J Epidemiol* **165**, 998–1006.
80. Chen H, Zhang SM, Hernán MA *et al.* (2002) Diet and Parkinson's disease: a potential role of dairy products in men. *Ann Neurol* **52**, 793–801.
81. Park M, Ross GW, Petrovitch H *et al.* (2005) Consumption of milk and calcium in midlife and the future risk of Parkinson disease. *Neurology* **64**, 1047–1051.
82. Jiang W, Ju C, Jiang H *et al.* (2014) Dairy foods intake and risk of Parkinson's disease: a dose-response meta-analysis of prospective cohort studies. *Eur J Epidemiol* **29**, 613–619.
83. Zhang X, Chen X, Xu Y *et al.* (2021) Milk consumption and multiple health outcomes: umbrella review of systematic reviews and meta-analyses in humans. *Nutr Metab (Lond)* **18**, 7.
84. Chrysohoou C, Panagiotakos DB, Pitsavos C *et al.* (2004) Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: the ATTICA study. *J Am Coll Cardiol* **44**, 152–158.
85. Sofi F, Cesari F, Abbate R *et al.* (2008) Adherence to Mediterranean diet and health status: meta-analysis. *Br Med J* **337**, a1344.
86. Sofi F, Abbate R, Gensini GF *et al.* (2010) Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. *Am J Clin Nutr* **92**, 1189–1196.
87. Gu Y, Brickman AM, Stern Y *et al.* (2015) Mediterranean diet and brain structure in a multiethnic elderly cohort. *Neurology* **85**, 1744–1751.
88. Gao X, Chen H, Fung TT *et al.* (2007) Prospective study of dietary pattern and risk of Parkinson disease. *Am J Clin Nutr* **86**, 1486–1494.
89. Anastasiou CA, Yannakoulia M, Kosmidis MH *et al.* (2017) Mediterranean diet and cognitive health: initial results from the hellenic longitudinal investigation of ageing and diet. *PLoS One* **12**, e0182048.
90. Gardener H & Caunca MR (2018) Mediterranean diet in preventing neurodegenerative diseases. *Curr Nutr Rep* **7**, 10–20.
91. Molsberry S, Bjornevik K, Hughes KC *et al.* (2020) Diet pattern and prodromal features of Parkinson disease. *Neurology* **95**, e2095–e2108.
92. Maraki MI, Yannakoulia M, Stamelou M *et al.* (2019) Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease. *Mov Disord* **34**, 48–57.
93. Yin W, Löf M, Pedersen NL *et al.* (2021) Mediterranean dietary pattern at middle age and risk of Parkinson's disease: a Swedish cohort study. *Mov Disord* **36**, 255–260.
94. Metcalfe-Roach A, Yu AC, Golz E *et al.* (2021) MIND and Mediterranean diets associated with later onset of Parkinson's disease. *Mov Disord* **36**, 977–984.
95. Agarwal P, Wang Y, Buchman AS *et al.* (2018) MIND diet associated with reduced incidence and delayed progression of ParkinsonismA in old age. *J Nutr Health Aging* **22**, 1211–1215.
96. Włodarek D (2019) Role of ketogenic diets in neurodegenerative diseases (Alzheimer's disease and Parkinson's disease). *Nutrients* **11**, 169.
97. Okubo H, Miyake Y, Sasaki S *et al.* (2012) Dietary patterns and risk of Parkinson's disease: a case-control study in Japan. *Eur J Neurol* **19**, 681–688.
98. Sharma JC & Turton J (2012) Olfaction, dyskinesia and profile of weight change in Parkinson's disease: identifying neurodegenerative phenotypes. *Parkinsonism Relat Disord* **18**, 964–970.
99. Chen H, Zhang SM, Hernán MA *et al.* (2003) Weight loss in Parkinson's disease. *Ann Neurol* **53**, 676–679.
100. Ragonese P, D'Amelio M, Callari G *et al.* (2008) Body mass index does not change before Parkinson's disease onset. *Eur J Neurol* **15**, 965–968.
101. van der Marck MA, Dicke HC, Uc EY *et al.* (2012) Body mass index in Parkinson's disease: a meta-analysis. *Parkinsonism Relat Disord* **18**, 263–267.
102. Yong VW, Tan YJ, Ng YD *et al.* (2020) Progressive and accelerated weight and body fat loss in Parkinson's disease: a three-year prospective longitudinal study. *Parkinsonism Relat Disord* **77**, 28–35.
103. Sheard JM, Ash S, Mellick GD *et al.* (2013) Malnutrition in a sample of community-dwelling people with Parkinson's disease. *PLoS One* **8**, e53290.
104. Cheshire WP Jr & Wszolek ZK (2005) Body mass index is reduced early in Parkinson's disease. *Parkinsonism Relat Disord* **11**, 35–38.
105. Barichella M, Marczevska A, Vairo A *et al.* (2003) Is underweightness still a major problem in Parkinson's disease patients? *Eur J Clin Nutr* **57**, 543–547.
106. Morales-Briceño H, Cervantes-Arriaga A, Rodríguez-Violante M *et al.* (2012) Overweight is more prevalent in patients with Parkinson's disease. *Arg Neuropsiquiatr* **70**, 843–846.
107. Kim HJ, Oh ES, Lee JH *et al.* (2012) Relationship between changes of body mass index (BMI) and cognitive

- decline in Parkinson's disease (PD). *Arch Gerontol Geriatr* **55**, 70–72.
108. Park K, Oeda T, Kohsaka M *et al.* (2018) Low body mass index and life prognosis in Parkinson's disease. *Parkinsonism Relat Disord* **55**, 81–85.
 109. Cumming K, Macleod AD, Myint PK *et al.* (2017) Early weight loss in parkinsonism predicts poor outcomes: evidence from an incident cohort study. *Neurology* **89**, 2254–2261.
 110. Ma K, Xiong N, Shen Y *et al.* (2018) Weight loss and malnutrition in patients with Parkinson's disease: current knowledge and future prospects. *Front Aging Neurosci* **10**, 1.
 111. Ross GW, Abbott RD, Petrovitch H *et al.* (2012) Pre-motor features of Parkinson's disease: the Honolulu-Asia aging study experience. *Parkinsonism Relat Disord* **18**, S199–S202.
 112. Abbott RD, Ross GW, Petrovitch H *et al.* (2007) Bowel movement frequency in late-life and incidental Lewy bodies. *Mov Disord* **22**, 1581–1586.
 113. Barichella M, Cereda E, Faierman SA *et al.* (2020) Resting energy expenditure in Parkinson's disease patients under dopaminergic treatment. *Nutr Neurosci*, 1–10. doi: 10.1080/1028415X.2020.1745427.
 114. Toth MJ, Fishman PS & Poehlman ET (1997) Free-living daily energy expenditure in patients with Parkinson's disease. *Neurology* **48**, 88–91.
 115. Tuite PJ, Maxwell RE, Ikramuddin S *et al.* (2005) Weight and body mass index in Parkinson's disease patients after deep brain stimulation surgery. *Parkinsonism Relat Disord* **11**, 247–252.
 116. Strowd RE, Cartwright MS, Passmore LV *et al.* (2010) Weight change following deep brain stimulation for movement disorders. *J Neurol* **257**, 1293–1297.
 117. Steinhart J, Münte TF, Schmid SM *et al.* (2020) A systematic review of body mass gain after deep brain stimulation of the subthalamic nucleus in patients with Parkinson's disease. *Obes Rev* **21**, e12955.
 118. Kelly MJ, Baig F, Hu MT *et al.* (2020) Spectrum of impulse control behaviours in Parkinson's disease: pathophysiology and management. *J Neurol Neurosurg Psychiatry* **91**, 703–711.
 119. de Chazeron I, Durif F, Lambert C *et al.* (2021) A case-control study investigating food addiction in Parkinson patients. *Sci Rep* **11**, 10934.
 120. de Chazeron I, Durif F, Chereau-Boudet I *et al.* (2019) Compulsive eating behaviors in Parkinson's disease. *Eat Weight Disord* **24**, 421–429.
 121. Lorefält B, Granérus AK & Unosson M (2006) Avoidance of solid food in weight losing older patients with Parkinson's disease. *J Clin Nurs* **15**, 1404–1412.
 122. Meyers C, Amick MA & Friedman JH (2010) Ice cream preference in Parkinson's disease. *Med Health R I* **93**, 91–92.
 123. Palavra NC, Lubomski M, Flood VM *et al.* (2021) Increased added sugar consumption is common in Parkinson's disease. *Front Nutr* **8**, 628845.
 124. Wolz M, Kaminsky A, Löhle M *et al.* (2009) Chocolate consumption is increased in Parkinson's disease. Results from a self-questionnaire study. *J Neurol* **256**, 488–492.
 125. Ådén E, Carlsson M, Poortvliet E *et al.* (2011) Dietary intake and olfactory function in patients with newly diagnosed Parkinson's disease: a case-control study. *Nutr Neurosci* **14**, 25–31.
 126. Drouot X, Moutereau S, Lefaucheur JP *et al.* (2011) Low level of ventricular CSF orexin-A is not associated with objective sleepiness in PD. *Sleep Med* **12**, 936–937.
 127. Chieffi S, Carotenuto M, Monda V *et al.* (2017) Orexin system: the key for a healthy life. *Front Physiol* **8**, 357.
 128. Fiszer U, Michałowska M, Baranowska B *et al.* (2010) Leptin and ghrelin concentrations and weight loss in Parkinson's disease. *Acta Neurol Scand* **121**, 230–236.
 129. Unger MM, Möller JC, Mankel K *et al.* (2011) Postprandial ghrelin response is reduced in patients with Parkinson's disease and idiopathic REM sleep behaviour disorder: a peripheral biomarker for early Parkinson's disease? *J Neurol* **258**, 982–990.
 130. Rahnemayan S, Mirghafourvand M, Fathalizadeh A *et al.* (2021) Leptin levels in patients with Parkinson's disease: a systematic review and meta-analysis. *Clin Nutr ESPEN* **41**, 104–109.
 131. Park J-S, Davis RL & Sue CM (2018) Mitochondrial dysfunction in Parkinson's disease: new mechanistic insights and therapeutic perspectives. *Curr Neurol Neurosci Rep* **18**, 21–21.
 132. Sheard JM, Ash S, Silburn PA *et al.* (2011) Prevalence of malnutrition in Parkinson's disease: a systematic review. *Nutr Rev* **69**, 520–532.
 133. Yang T, Zhan Z, Zhang L *et al.* (2020) Prevalence and risk factors for malnutrition in patients With Parkinson's disease. *Front Neurol* **11**, 1–7.
 134. Paul BS, Singh T, Paul G *et al.* (2019) Prevalence of malnutrition in Parkinson's disease and correlation with gastrointestinal symptoms. *Ann Indian Acad Neurol* **22**, 447–452.
 135. Beaudart C, Sanchez-Rodriguez D, Locquet M *et al.* (2019) Malnutrition as a strong predictor of the onset of sarcopenia. *Nutrients* **11**, 1–13.
 136. Cruz-Jentoft AJ, Kiesswetter E, Drey M *et al.* (2017) Nutrition, frailty, and sarcopenia. *Aging Clin Exp Res* **29**, 43–48.
 137. Gómez-Gómez ME & Zapico SC (2019) Frailty, cognitive decline, neurodegenerative diseases and nutrition interventions. *Int J Mol Sci* **20**, 1–18.
 138. Morley JE, Baumgartner RN, Roubenoff R *et al.* (2001) Sarcopenia. *J Lab Clin Med* **137**, 231–243.
 139. Cruz-Jentoft AJ, Baeyens JP, Bauer JM *et al.* (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. *Age Ageing* **39**, 412–423.
 140. Cruz-Jentoft AJ, Bahat G, Bauer J *et al.* (2019) Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* **48**, 16–31.
 141. Studenski SA, Peters KW, Alley DE *et al.* (2014) The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. *J Gerontol A Biol Sci Med Sci* **69**, 547–558.
 142. Fielding RA, Vellas B, Evans WJ *et al.* (2011) Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. *J Am Med Dir Assoc* **12**, 249–256.
 143. Burgos R, Bretón I, Cereda E *et al.* (2018) ESPEN guideline clinical nutrition in neurology. *Clin Nutr* **37**, 354–396.
 144. Barichella M, Pinelli G, Iorio L *et al.* (2016) Sarcopenia and dynapenia in patients with parkinsonism. *J Am Med Dir Assoc* **17**, 640–646.
 145. Ozer FF, Akin S, Gultekin M *et al.* (2020) Sarcopenia, dynapenia, and body composition in Parkinson's disease: are they good predictors of disability?: a case-control study. *Neurol Sci* **41**, 313–320.
 146. da Luz MCL, Bezerra GKA, Asano AGC *et al.* (2021) Determinant factors of sarcopenia in individuals with Parkinson's disease. *Neurol Sci* **42**, 979–985.



147. Tan YJ, Lim SY, Yong VW *et al.* (2021) Osteoporosis in Parkinson's disease: relevance of distal radius dual-energy X-ray absorptiometry (DXA) and sarcopenia. *J Clin Densitom* **24**, 351–361.
148. Chen LK, Liu LK, Woo J *et al.* (2014) Sarcopenia in Asia: consensus report of the Asian working group for sarcopenia. *J Am Med Dir Assoc* **15**, 95–101.
149. Vetrano DL, Pisciotta MS, Laudisio A *et al.* (2018) Sarcopenia in Parkinson disease: comparison of different criteria and association with disease severity. *J Am Med Dir Assoc* **19**, 523–527.
150. Torsney KM, Noyce AJ, Doherty KM *et al.* (2014) Bone health in Parkinson's disease: a systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry* **85**, 1159–1166.
151. Liu B, Chen G, Yu Z *et al.* (2021) Bone mineral density and related scores in Parkinson's disease: a systematic review and meta-analysis. *World Neurosurg* **146**, e1202–e1218.
152. Tan L, Wang Y, Zhou L *et al.* (2014) Parkinson's disease and risk of fracture: a meta-analysis of prospective cohort studies. *PLoS One* **9**, e94379.
153. Hely MA, Reid WG, Adena MA *et al.* (2008) The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. *Mov Disord* **23**, 837–844.
154. Bhattacharya RK, Dubinsky RM, Lai SM *et al.* (2012) Is there an increased risk of hip fracture in Parkinson's disease? A nationwide inpatient sample. *Mov Disord* **27**, 1440–1442.
155. Genever RW, Downes TW & Medcalf P (2005) Fracture rates in Parkinson's disease compared with age- and gender-matched controls: a retrospective cohort study. *Age Ageing* **34**, 21–24.
156. Schneider JL, Fink HA, Ewing SK *et al.* (2008) The association of Parkinson's disease with bone mineral density and fracture in older women. *Osteoporosis Int* **19**, 1093–1097.
157. Fink HA, Kuskowski MA, Taylor BC *et al.* (2008) Association of Parkinson's disease with accelerated bone loss, fractures and mortality in older men: the osteoporotic fractures in Men (MrOS) study. *Osteoporosis Int* **19**, 1277–1282.
158. Schini M, Vilaca T, Poku E *et al.* (2020) The risk of hip and non-vertebral fractures in patients with Parkinson's disease and parkinsonism: a systematic review and meta-analysis. *Bone* **132**, 115173.
159. Lee CK, Choi SK, Shin DA *et al.* (2018) Parkinson's disease and the risk of osteoporotic vertebral compression fracture: a nationwide population-based study. *Osteoporosis Int* **29**, 1117–1124.
160. Kalilani L, Asgharnejad M, Palokangas T *et al.* (2016) Comparing the incidence of falls/fractures in Parkinson's disease patients in the US population. *PLoS One* **11**, e0161689.
161. Sleeman I, Che ZC & Counsell C (2016) Risk of fracture amongst patients with Parkinson's disease and other forms of Parkinsonism. *Parkinsonism Relat Disord* **29**, 60–65.
162. Dennison EM, Compston JE, Flahive J *et al.* (2012) Effect of co-morbidities on fracture risk: findings from the global longitudinal study of osteoporosis in women (GLOW). *Bone* **50**, 1288–1293.
163. Coomber R, Alshameeri Z, Masia AF *et al.* (2017) Hip fractures and Parkinson's disease: a case series. *Injury* **48**, 2730–2735.
164. Chen YY, Cheng PY, Wu SL *et al.* (2012) Parkinson's disease and risk of hip fracture: an 8-year follow-up study in Taiwan. *Parkinsonism Relat Disord* **18**, 506–509.
165. Mühlenfeld N, Söhling N, Marzi I *et al.* (2021) Fractures in Parkinson's disease: injury patterns, hospitalization, and therapeutic aspects. *Eur J Trauma Emerg Surg* **47**, 573–580.
166. Walker RW, Chaplin A, Hancock RL *et al.* (2013) Hip fractures in people with idiopathic Parkinson's disease: incidence and outcomes. *Mov Disord* **28**, 334–340.
167. Crego-Vita D, Sanchez-Perez C, Gomez-Rico JA *et al.* (2017) Intracapsular hip fractures in the elderly. Do we know what is important? *Injury* **48**, 695–700.
168. Abou-Raya S, Helmii M & Abou-Raya A (2009) Bone and mineral metabolism in older adults with Parkinson's disease. *Age Ageing* **38**, 675–680.
169. van den Bos F, Speelman AD, van Nimwegen M *et al.* (2013) Bone mineral density and vitamin D status in Parkinson's disease patients. *J Neurol* **260**, 754–760.
170. Peterson AL, Mancini M & Horak FB (2013) The relationship between balance control and vitamin D in Parkinson's disease—a pilot study. *Mov Disord* **28**, 1133–1137.
171. Tarakad A & Jankovic J (2017) Anosmia and ageusia in Parkinson's disease. *Int Rev Neurobiol* **133**, 541–556.
172. Shah M, Deeb J, Fernando M *et al.* (2009) Abnormality of taste and smell in Parkinson's disease. *Parkinsonism Relat Disord* **15**, 232–237.
173. Andersson I & Sidenvall B (2001) Case studies of food shopping, cooking and eating habits in older women with Parkinson's disease. *J Adv Nurs* **35**, 69–78.
174. Masala C, Loy F, Piras R *et al.* (2020) Effect of olfactory and gustatory dysfunction and motor symptoms on body weight in patients with Parkinson's disease. *Brain Sci* **10**, 218.
175. Roos DS, Oranje OJM, Freriksen AFD *et al.* (2018) Flavor perception and the risk of malnutrition in patients with Parkinson's disease. *J Neural Transm* **125**, 925–930.
176. Kalf JG, de Swart BJ, Bloem BR *et al.* (2012) Prevalence of oropharyngeal dysphagia in Parkinson's disease: a meta-analysis. *Parkinsonism Relat Disord* **18**, 311–315.
177. Simons JA (2017) Swallowing dysfunctions in Parkinson's disease. *Int Rev Neurobiol* **134**, 1207–1238.
178. Umemoto G, Fujioka S, Iwasa Y *et al.* (2021) Impact of progression of Parkinson's disease on swallowing ability and oral environment. *Parkinsons Dis* **2021**, 5571556–5571556.
179. Hanaoka A & Kashihara K (2009) Increased frequencies of caries, periodontal disease and tooth loss in patients with Parkinson's disease. *J Clin Neurosci* **16**, 1279–1282.
180. Coon EA & Laughlin RS (2012) Burning mouth syndrome in Parkinson's disease: dopamine as cure or cause? *J Headache Pain* **13**, 255–257.
181. Ou R, Wei Q, Hou Y *et al.* (2021) Facial tremor in patients with Parkinson's disease: prevalence, determinants and impacts on disease progression. *BMC Neurol* **21**, 86.
182. Carneiro D, das Graças Wanderley de Sales Coriolano M, Belo LR *et al.* (2014) Quality of life related to swallowing in Parkinson's disease. *Dysphagia* **29**, 578–582.
183. Pennington S, Snell K, Lee M *et al.* (2010) The cause of death in idiopathic Parkinson's disease. *Parkinsonism Relat Disord* **16**, 434–437.
184. Li X, Feng X, Jiang Z *et al.* (2021) Association of small intestinal bacterial overgrowth with Parkinson's disease: a systematic review and meta-analysis. *Gut Pathog* **13**, 25.
185. Boulos C, Yaghi N, El Hayeck R *et al.* (2019) Nutritional risk factors, Microbiota and Parkinson's disease: what is the current evidence? *Nutrients* **11**, 1–24.



186. Bures J, Cyrany J, Kohoutova D *et al.* (2010) Small intestinal bacterial overgrowth syndrome. *World J Gastroenterol* **16**, 2978–2990.
187. Hasuike Y, Endo T, Koroyasu M *et al.* (2020) Bile acid abnormality induced by intestinal dysbiosis might explain lipid metabolism in Parkinson's disease. *Med Hypotheses* **134**, 109436.
188. Dardiotis E, Tsouris Z, Mentis AA *et al.* (2018) *H. pylori* and Parkinson's disease: meta-analyses including clinical severity. *Clin Neurol Neurosurg* **175**, 16–24.
189. Bai F & Li X (2021) Association of *Helicobacter pylori* treatment with Parkinsonism and related disorders: a systematic review and meta-analysis. *Life Sci* **281**, 119767.
190. Sakakibara R (2021) Gastrointestinal dysfunction in movement disorders. *Neurol Sci* **42**, 1355–1365.
191. Picillo M, Palladino R, Erro R *et al.* (2021) The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson's disease. *J Neurol* **268**, 448–454.
192. Camacho M, Macleod AD, Maple-Grødem J *et al.* (2021) Early constipation predicts faster dementia onset in Parkinson's disease. *NPJ Parkinsons Dis* **7**, 45.
193. Ohlsson B & Englund E (2019) Atrophic myenteric and submucosal neurons are observed in Parkinson's disease. *Parkinsons Dis* **2019**, 7935820.
194. Yu D, Ramsey FV, Norton WF *et al.* (2017) The burdens, concerns, and quality of life of patients with gastroparesis. *Dig Dis Sci* **62**, 879–893.
195. Doi H, Sakakibara R, Sato M *et al.* (2012) Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease. *J Neurol Sci* **319**, 86–88.
196. Fávoro-Moreira NC, Krausch-Hofmann S, Matthys C *et al.* (2016) Risk factors for malnutrition in older adults: a systematic review of the literature based on longitudinal data. *Adv Nutr* **7**, 507–522.
197. Evidence based practice guidelines for the nutritional management of malnutrition in adult patients across the continuum of care (2019). *Nutr Diet* **66**, S1–S34.
198. Sheard JM, Ash S, Silburn PA *et al.* (2013) Nutritional status in Parkinson's disease patients undergoing deep brain stimulation surgery: a pilot study. *J Nutr Health Aging* **17**, 148–151.
199. Wang G, Wan Y, Cheng Q *et al.* (2010) Malnutrition and associated factors in Chinese patients with Parkinson's disease: results from a pilot investigation. *Parkinsonism Relat Disord* **16**, 119–123.
200. Athlin E, Norberg A, Axelsson K *et al.* (1989) Aberrant eating behavior in elderly parkinsonian patients with and without dementia: analysis of video-recorded meals. *Res Nurs Health* **12**, 41–51.
201. Fagerberg P, Klingelhofer L, Bottai M *et al.* (2020) Lower energy intake among advanced vs. early Parkinson's disease patients and healthy controls in a clinical lunch setting: a cross-sectional study. *Nutrients* **12**, 2109.
202. De Lucia N, Peluso S, Esposito M *et al.* (2020) Frontal defect contribution to decreasing of body mass index in Parkinson's disease patients. *J Clin Neurosci* **72**, 229–232.
203. Jung D, De Gagne JC, Lee H *et al.* (2021) Factors associated with eating performance in older adults with dementia in long-term care facilities: a cross-sectional study. *BMC Geriatr* **21**, 365.
204. Kaiser MJ, Bauer JM, Rämisch C *et al.* (2010) Frequency of malnutrition in older adults: a multinational perspective using the mini nutritional assessment. *J Am Geriatr Soc* **58**, 1734–1738.
205. Liu W, Jao YL & Williams K (2017) The association of eating performance and environmental stimulation among older adults with dementia in nursing homes: a secondary analysis. *Int J Nurs Stud* **71**, 70–79.
206. Reijnders JS, Ehrt U, Weber WE *et al.* (2008) A systematic review of prevalence studies of depression in Parkinson's disease. *Mov Disord* **23**, 183–189, quiz 313.
207. Kim SR, Chung SJ & Yoo SH (2016) Factors contributing to malnutrition in patients with Parkinson's disease. *Int J Nurs Pract* **22**, 129–137.
208. Wills AM, Li R, Pérez A *et al.* (2017) Predictors of weight loss in early treated Parkinson's disease from the NET-PD LS-1 cohort. *J Neurol* **264**, 1746–1753.
209. Artaud F, Lee PC, Mangone G *et al.* (2020) Longitudinal association between dopamine agonists and weight in Parkinson's disease. *Parkinsonism Relat Disord* **80**, 158–164.
210. Fabbri M, Zibetti M, Beccaria L *et al.* (2019) Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease. *Eur J Neurol* **26**, 490–496.
211. Muhlack S, Kinkel M, Herrman L *et al.* (2017) Levodopa, placebo and rotigotine change biomarker levels for oxidative stress. *Neurol Res* **39**, 381–386.
212. Taher J, Naranian T, Poon YY *et al.* (2021) Vitamins and infusion of levodopa-carbidopa intestinal gel. *Can J Neurol Sci*, 1–10. doi: 10.1017/cjn.2021.78.
213. Balestrino R, Baroncini D, Fichera M *et al.* (2017) Weight gain after subthalamic nucleus deep brain stimulation in Parkinson's disease is influenced by dyskinesias' reduction and electrodes' position. *Neurol Sci* **38**, 2123–2129.
214. Arabia G, Zappia M, Bosco D *et al.* (2002) Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease. *Neurol Sci* **23**(Suppl 2), S53–S54.
215. Sharma JC, Macnamara L, Hasoon M *et al.* (2006) Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade). *Parkinsonism Relat Disord* **12**, 499–505.
216. Zappia M, Crescibene L, Arabia G *et al.* (2002) Body weight influences pharmacokinetics of levodopa in Parkinson's disease. *Clin Neuropharmacol* **25**, 79–82.
217. Adams F, Boschmann M, Lobsien E *et al.* (2008) Influences of levodopa on adipose tissue and skeletal muscle metabolism in patients with idiopathic Parkinson's disease. *Eur J Clin Pharmacol* **64**, 863–870.
218. Ceravolo R, Cossu G, Bandettini di Poggio M *et al.* (2013) Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. *Mov Disord* **28**, 1391–1397.
219. British Dietetic Association. Best practice guidance for dietitians on the nutritional management of Parkinson's.